Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies

Journal of Clinical Oncology

Volumn 20, Issue 11, 2002, Pages 2616-2623

  Nadella, Padma ^a   Shapiro, Charles ^a   Otterson, Gregory A ^a   Hauger, Marsha ^a   Erdal, Selnur ^a   Kraut, Eric ^a   Clinton, Steven ^a   Shah, Manisha ^a   Stanek, Mike ^a   Monk, Paul ^a   Villalona Calero, Miguel A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; MITOMYCIN C; PACLITAXEL; THYMIDINE PHOSPHORYLASE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLADDER CARCINOMA; BLOOD TOXICITY; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TAXOIDS; THYMIDINE PHOSPHORYLASE;

EID: 0036605799     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.22.030     Document Type: Article

References (32)

1. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
2. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
3. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine
4. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts
5. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
6. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients
7. Efficacy and safety profile of capecitabine (Xeloda) in combination with paclitaxel (P) in patients with locally advanced or metastatic breast cancer: Preliminary results of a phase II study
8. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
9. Results of a large phase III trial of Xeloda/Taxotere combination therapy vs. Taxotere monotherapy in metastatic breast cancer (MBC) patients
10. Single agent paclitaxel in the treatment of breast cancer: Phase I and II development
11. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
12. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial
13. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
14. A phase II study of Xeloda (capecitabine) in patients with metastatic colorectal cancer demonstrating progression on 5-FU therapy
15. Phase II trial of docetaxel (taxotere) in metastatic colorectal carcinoma
16. Phase II trial of docetaxel (taxotere) for untreated advanced colorectal carcinoma
17. Effect of excess folate and deoxyinosine on the activity and site of action of 5-fluorouracil
18. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil
19. Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: A murine study with clinical relevance
20. Interaction of fluorouracil and interferon in human colon cancer cell lines: Cytotoxic and cytokinetic effects
21. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and of 5-fluorouracil in rodents
22. 5-Ethynyluracil (776C85): A potent modulator of the pharmacology and antitumor efficacy of 5-fluorouracil
23. Phase I and pharmacologic study of PN 401 and fluorouracil in patients with advanced solid malignancies
24. Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonoacetylaspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study
25. Cancer and Leukemia Group B: Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma
26. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
27. Schedule dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cells in vitro
28. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells
29. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
30. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients
31. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models